The good news is that AI is no longer only for the big tech companies. It's now a productivity accelerator for individuals, ...

Ardelyx (ARDX) is emerging as a compelling, yet risky, small-cap biotech opportunity. The company has made significant progress with two first-in-class therapies: IBSRELA (tenapanor) for irritable ...